Nucleic acid aptamers, often termed'chemical antibodies', are functionally comparable to
traditional antibodies, but offer several advantages, including their relatively small physical …

Inactivation of the transcription factor p53, through either direct mutation or aberrations in
one of its many regulatory pathways, is a hallmark of virtually every tumor. In recent years …

Somatic mutations in p53, which inactivate the tumour-suppressor function of p53 and often
confer oncogenic gain-of-function properties, are very common in cancer,. Here we studied …

TP53 is the most frequently mutated gene in cancer, yet these mutations remain
therapeutically non-actionable. Major challenges in drugging p53 mutations include …

Glioblastoma (GBM) is the most devastating brain tumor and highly resistant to conventional
chemotherapy. Herein, we introduce biomimetic nanosonosensitizer systems (MDNPs) …

Inactivation of the p53 tumor suppressor is a frequent event in tumorigenesis. In most cases,
the p53 gene is mutated, giving rise to a stable mutant protein whose accumulation is …

The p53 protein is mutated in about 50% of human cancers. Aside from losing the tumor-
suppressive functions of the wild-type form, mutant p53 proteins often acquire inherent …

Half of all human cancers lose p53 function by missense mutations, with an unknown
fraction of these containing p53 in a self-aggregated amyloid-like state. Here we show that a …

The manner in which a newly synthesized chain of amino acids transforms itself into a
perfectly folded protein depends both on the intrinsic properties of the amino-acid sequence …

Cisplatin is one of the most potent antitumor agents known, displaying clinical activity
against a wide variety of solid tumors. Its cytotoxic mode of action is mediated by its …